Summary of Protagonist Therapeutics Conference Call Company Overview - **Company**: Protagonist Therapeutics (NasdaqGM:PTGX) - **Key Product**: ICOTYDE, an oral peptide-targeted therapy for moderate-to-severe plaque psoriasis Key Industry and Company Insights FDA Approval Announcement - Protagonist announced FDA approval of ICOTYDE for treating moderate-to-severe plaque psoriasis in adults and pediatric patients aged 12 and older who weigh at least 40 kg [2][4] - ICOTYDE is the first oral peptide-targeted therapy that blocks the IL-23 pathway by targeting the IL-23 receptor, contrasting with existing injectable antibodies that target the IL-23 ligand [4][6] Clinical Development and Efficacy - The approval was supported by a comprehensive phase 3 program involving approximately 2,500 patients across four studies, meeting all primary endpoints and demonstrating a favorable safety profile [7][9] - ICOTYDE has a broad label based on studies in both adults and adolescents, including head-to-head studies showing superiority to the active comparator, Sotyktu [8] Financial Implications - The approval triggers a $50 million milestone payment from Johnson & Johnson (J&J) and initiates a royalty-based revenue stream [10] - Protagonist has earned a total of $387 million in milestone payments since the collaboration with J&J began in 2017, with an additional $580 million in potential future milestones [10][11] - The royalty structure includes tiered royalties ranging from 6% to 10% on global net sales, with a weighted average of 7.25% at $4 billion in annual sales [12] Strategic Partnerships - Protagonist emphasizes the importance of its collaboration with J&J, which is responsible for commercialization and ongoing clinical trials of ICOTYDE [13] - The partnership has been described as a win-win, highlighting the potential blockbuster category of ICOTYDE [13] Pipeline and Future Developments Additional Assets - Protagonist is expecting FDA approval for rusfertide, a hepcidin mimetic for polycythemia vera, in the third quarter of the year [14][15] - The company is developing new R&D assets, including an oral IL-17 peptide antagonist (PN881) and an oral triple GLP GIP GCG agonist (PN477) for obesity [16][17] Financial Position and Shareholder Value - Protagonist aims to fund its R&D programs without equity offerings, focusing on returning capital to shareholders through potential share buybacks [19][20] - The company is exploring partnerships for its IL-17 and obesity programs, with ongoing dialogues with multiple parties [107] Market Position and Competitive Landscape - Protagonist believes ICOTYDE can capture market share from existing injectables and attract patients currently not on treatment due to aversion to injections [53][54] - The company is focused on differentiating its products in a competitive landscape, particularly in the obesity space where unmet needs exist [77][96] Conclusion - The approval of ICOTYDE marks a significant milestone for Protagonist, validating its peptide technology platform and setting the stage for future growth and product-driven cycles [20][22] - The company is well-positioned financially and strategically to expand its pipeline and enhance shareholder value through innovative therapies and partnerships.

Core Viewpoint - Entera Bio Ltd. has presented promising preclinical data for its oral GLP-2 analog, OPK-8801003, which could significantly improve treatment for Short Bowel Syndrome (SBS) patients who currently rely on daily injections of the peptide [1][3]. Company Overview - Entera Bio is a clinical-stage company focused on developing oral peptide and protein replacement therapies, leveraging its proprietary N-Tab™ technology platform [6]. - The company is collaborating with OPKO Health, Inc. to develop oral peptide candidates for intestinal malabsorption syndromes, specifically targeting SBS [2][8]. Product Development - OPK-8801003 demonstrated a plasma half-life of approximately 15 hours in preclinical studies, an 18-fold improvement over the current treatment, teduglutide, which has a half-life of only 0.85 hours [7]. - The peak plasma concentration of OPK-8801003 reached ~200 ng/ml, significantly higher than the reported Cmax of 36.8 ng/ml for teduglutide [7]. - The systemic exposure (AUC) was maintained for over 24 hours, supporting the potential for once-daily oral dosing [7]. Market Context - Approximately 30,000 patients in the U.S. and EU suffer from SBS, with the only approved therapy, Gattex® (teduglutide), generating around $800 million in annual sales [5][2]. - SBS is a leading cause of chronic intestinal failure, accounting for about 75% of cases in adults and 50% in children [5]. Future Implications - The robust oral bioavailability and favorable safety profile of OPK-8801003 could fundamentally change the treatment landscape for SBS, offering a less invasive administration method and personalized dosing options [3][7].